Stable overexpression of arginase I and ornithine transcarbamylase in HepG2 cells improves its ammonia detoxification

Journal of Cellular Biochemistry

Volumn 113, Issue 2, 2012, Pages 518-527

  Tang, Nanhong ^a   Wang, Yan ^a   Wang, Xiaoqian ^a   Zhou, Liangyi ^a   Zhang, Feiyuan ^a   Li, Xiujin ^a   Chen, Yanlin ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Bioartificial liver; Glutamine; Urea cycle

Indexed keywords

AMMONIA; ARGINASE; ARGINASE 1; ARGININOSUCCINATE LYASE; ARGININOSUCCINATE SYNTHASE; GLUTAMATE AMMONIA LIGASE; ORNITHINE CARBAMOYLTRANSFERASE;

ARTICLE; CELL CULTURE; CELL FUNCTION; CELL PROLIFERATION; CELL STRAIN HEPG2; CONTROLLED STUDY; DETOXIFICATION; ENZYME ACTIVITY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LIVER CELL; PRIORITY JOURNAL;

AMMONIA; ARGINASE; ARGININOSUCCINATE LYASE; ARGININOSUCCINATE SYNTHASE; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUTAMATE-AMMONIA LIGASE; GLUTAMINE; HEP G2 CELLS; HUMANS; LIVER, ARTIFICIAL; METABOLIC ENGINEERING; ORNITHINE CARBAMOYLTRANSFERASE; RECOMBINANT PROTEINS; UREA;

EUKARYOTA;

EID: 84862932536     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23375     Document Type: Article

References (30)

1. Albrecht J, Dolinska M. 2001. Glutamine as a pathogenic factor in hepatic encephalopathy. J Neurosci Res 65:1-5. (Pubitemid 32601305)
2. Ash DE. 2004. Structure and function of arginases. J Nutr 134:2760S-2764S, discussion 2765S-2767S.
3. Cederbaum SD, Yu H, Grody WW, Kern RM, Yoo P, Iyer RK. 2004. Arginases I and II: Do their functions overlap? Mol Genet Metab 81(Suppl 1):S38-S44. (Pubitemid 38402233)
4. Cheng PN, Lam TL, Lam WM, Tsui SM, Cheng AW, Lo WH, Leung YC. 2007. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res 67:309-317. (Pubitemid 46142789)
5. Chowdhury S, Gotoh T, Mori M, Takiguchi M. 1996. CCAAT/enhancer-binding protein beta (C/EBP beta) binds and activates while hepatocyte nuclear factor-4 (HNF-4) does not bind but represses the liver-type arginase promoter. Eur J Biochem 236:500-509. (Pubitemid 26099942)
6. Corraliza IM, Campo ML, Soler G, Modolell M. 1994. Determination of arginase activity in macrophages: A micromethod. J Immunol Methods 174:231-235. (Pubitemid 24297154)
7. Dejong CH, Deutz NE, Soeters PB. 1996. Ammonia and glutamine metabolism during liver insufficiency: The role of kidney and brain in interorgan nitrogen exchange. Scand J Gastroenterol Suppl 218:61-77. (Pubitemid 26261855)
8. Delers A, Szpirer J, Szpirer C, Saggioro D. 1984. Spontaneous and 5-azacytidine-induced reexpression of ornithine carbamoyl transferase in hepatoma cells. Mol Cell Biol 4:809-812. (Pubitemid 14130380)
9. Demetriou AA, Rozga J, Podesta L, Lepage E, Morsiani E, Moscioni AD, Hoffman A, McGrath M, Kong L, Rosen H. 1995. Early clinical experience with a hybrid bioartificial liver. Scand J Gastroenterol Suppl 208:111-117.
10. Enosawa S, Miyashita T, Suzuki S, Li XK, Tsunoda M, Amemiya H, Yamanaka M, Hiramatsu S, Tanimura N, Omasa T, Suga K, Matsumura T. 2000. Longterm culture of glutamine synthetase-transfected HepG2 cells in circulatory flow bioreactor for development of a bioartificial liver. Cell Transplant 9:711-715. (Pubitemid 32002581)
11. Enosawa S, Miyashita T, Saito T, Omasa T, Matsumura T. 2006. The significant improvement of survival times and pathological parameters by bioartificial liver with recombinant HepG2 in porcine liver failure model. Cell Transplant 15:873-880. (Pubitemid 46174536)
12. Filippi C, Keatch SA, Rangar D, Nelson LJ, Hayes PC, Plevris JN. 2004. Improvement of C3A cell metabolism for usage in bioartificial liver support systems. J Hepatol 41:599-605. (Pubitemid 39297795)
13. Fruhauf JH, Mertsching H, Giri S, Fruhauf NR, Bader A. 2009. Porcine endogenous retrovirus released by a bioartificial liver infects primary human cells. Liver Int 29:1553-1561.
14. Mavri-Damelin D, Eaton S, Damelin LH, Rees M, Hodgson HJ, Selden C. 2007. Ornithine transcarbamylase and arginase I deficiency are responsible for diminished urea cycle function in the human hepatoblastoma cell line HepG2. Int J Biochem Cell Biol 39:555-564. (Pubitemid 46096793)
15. Mavri-Damelin D, Damelin LH, Eaton S, Rees M, Selden C, Hodgson HJ. 2008. Cells for bioartificial liver devices: The human hepatoma-derived cell line C3A produces urea but does not detoxify ammonia. Biotechnol Bioeng 99:644-651. (Pubitemid 351158262)
16. Miyashita T, Enosawa S, Suzuki S, Tamura A, Tanaka H, Amemiya H, Matsumura T, Omasa T, Suga K, Aoki T, Koyanagi Y. 2000. Development of a bioartificial liver with glutamine synthetase-transduced recombinant human hepatoblastoma cell line, HepG2. Transplant Proc 32:2355-2358.
17. Morizono H, Tuchman M, Rajagopal BS, McCann MT, Listrom CD, Yuan X, Venugopal D, Barany G, Allewell NM. 1997. Expression, purification and kinetic characterization of wild-type human ornithine transcarbamylase and a recurrent mutant that produces 'late onset' hyperammonaemia. Biochem J 322(Pt 2):625-631. (Pubitemid 27116593)
18. Nakamura E, Hagen SJ. 2002. Role of glutamine and arginase in protection against ammonia-induced cell death in gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol 283:G1264-G1275. (Pubitemid 35351113)
19. Nibourg GA, Huisman MT, van der Hoeven TV, van Gulik TM, Chamuleau RA, Hoekstra R. 2010. Stable overexpression of pregnane X receptor in HepG2 cells increases its potential for bioartificial liver application. Liver Transpl 16:1075-1085.
20. Nyberg SL, Hibbs JR, Hardin JA, Germer JJ, Platt JL, Paya CV, Wiesner RH. 2000. Influence of human fulminant hepatic failure sera on endogenous retroviral expression in pig hepatocytes. Liver Transpl 6:76-84. (Pubitemid 30123372)
21. Pegg AE. 2006. Regulation of ornithine decarboxylase. J Biol Chem 281:14529-14532. (Pubitemid 43855154)
22. Sauer IM, Kardassis D, Zeillinger K, Pascher A, Gruenwald A, Pless G, Irgang M, Kraemer M, Puhl G, Frank J, Muller AR, Steinmuller T, Denner J, Neuhaus P, Gerlach JC. 2003. Clinical extracorporeal hybrid liver support-Phase I study with primary porcine liver cells. Xenotransplantation 10:460-469. (Pubitemid 37129891)
23. Scaglia F, Carter S, O'Brien WE, Lee B. 2004. Effect of alternative pathway therapy on branched chain amino acid metabolism in urea cycle disorder patients. Mol Genet Metab 81(Suppl 1):S79-S85. (Pubitemid 38402240)
24. Tang NH, Wang XQ, Li XJ, Chen YL. 2008. Ammonia metabolism capacity of HepG2 cells with high expression of human glutamine synthetase. Hepatobiliary Pancreat Dis Int 7:621-627.
25. van de Kerkhove MP, Di Florio E, Scuderi V, Mancini A, Belli A, Bracco A, Scala D, Scala S, Zeuli L, Di Nicuolo G, Amoroso P, Calise F, Chamuleau RA. 2003. Bridging a patient with acute liver failure to liver transplantation by the AMC-bioartificial liver. Cell Transplant 12:563-568. (Pubitemid 37204413)
26. Wallace HM, Fraser AV, Hughes A. 2003. A perspective of polyamine metabolism. Biochem J 376:1-14. (Pubitemid 37487199)
27. Wang L, Sun J, Li L, Mears D, Horvat M, Sheil AG. 1998. Comparison of porcine hepatocytes with human hepatoma (C3A) cells for use in a bioartificial liver support system. Cell Transplant 7:459-468. (Pubitemid 29046550)
28. Watanabe FD, Mullon CJ, Hewitt WR, Arkadopoulos N, Kahaku E, Eguchi S, Khalili T, Arnaout W, Shackleton CR, Rozga J, Solomon B, Demetriou AA. 1997. Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann Surg 225:484-491, discussion 491-494.
29. Wu G. 1995. Urea synthesis in enterocytes of developing pigs. Biochem J 312(Pt 3):717-723. (Pubitemid 26005979)
30. Zharikov S, Krotova K, Hu H, Baylis C, Johnson RJ, Block ER, Patel J. 2008. Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am J Physiol Cell Physiol 295:C1183-C1190. (Pubitemid 352790338)